Loading…
Aveanna Healthcare Holdings Inc.
🏹 Trader: ⭐ All Three 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High 📊 High Volume | BRS 97 Elite View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$2.7B
Market Cap
7.7
P/E
0.74
PEG
38.9%
ROCE
615.7%
ROE
7.58
D/E
10.5%
OPM
0.0%
% from 52W High
95
α RS
🔍 AVAH is showing a high-conviction setup because it matches 11 of 37 tracked screener presets, Sector RRG has Health Care in the Leading quadrant with the trail still strengthening, and RS Rating is 95 (top decile vs market). Net: Broad signal stack, not a recommendation. ? Conviction RRG RS Rating
Sources
Conviction 11/37 · Health Care in Leading quadrant · RS Rating 95
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for AVAH including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding AVAH
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 905.9K $5.8M 0.01% Mar 2026
Steve Cohen Point72 Asset Management 100.7K $648K 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
📊 MIXED Q1 revenue $648M, adj. EBITDA $84.4M; 2026 guidance raised.
Revenue & Profitability
Q1 2026 revenue was $647.9 million, up 15.9% YoY. Adjusted EBITDA of $84.4 million increased 25.2% YoY. Segment revenues: PDS $536 million (16.4% growth), Home Health & Hospice $66.6 million (17.4%), Medical Solutions $45.7 million (7.4%). Operating cash flow was $4.3 million and free cash flow was -$3.8 million. Liquidity stood at $525 million. Full-year 2026 guidance raised to revenue $2.56-$2.58 billion and adjusted EBITDA $328-$332 million.
Outlook
Management sees strong and growing demand for home and community-based care from government and managed care organizations seeking cost-effective alternatives. The labor market remains challenging but stable, with caregiver hiring and retention improving as rate increases are passed through as wages. Regulatory headwinds include a CMS moratorium on new Medicare Home Health licensure, but Aveanna views this as having no impact on its business.
Growth Drivers
Growth is driven by preferred payer agreements (signed 4 in PDS, 4 in Home Health, 2 in Medical Solutions in Q1) and volume expansion: PDS hours up 10.7%, Home Health admissions up 13.4% (episodes up 23.1%), Medical Solutions unique patients served up 4.5%. Geographic expansion into new states (e.g., Ohio, Michigan) and cross-selling opportunities from acquisitions like Family First Homecare (Florida) provide additional levers.
Balance Sheet & CapEx
CapEx in Q1 was $4.5 million, elevated due to a one-time laptop refresh program; this level is not expected to continue. The company is investing in artificial intelligence and automation across RCM, scheduling, and accounting to drive operational efficiencies. No specific full-year CapEx guidance was provided.
Margins
Consolidated gross margin was 31.7% in Q1. Segment margins: PDS gross margin 27.9% (spread per hour $12.38), Home Health & Hospice 53.7%, Medical Solutions 44.7%. Management expects margins to remain stable in these ranges, with slight improvements from automation and operating leverage. Caregiver wage increases are passed through from rate gains, keeping spread consistent.
Key Risks
Management cited continued labor market challenges, though conditions are stabilizing. Regulatory risks include potential Medicaid rate moderation and the CMS Home Health moratorium, which does not affect Aveanna. Other risks include the timing of the Family First acquisition, reliance on state and payer rate approvals, and conservatism in guidance due to one-time timing benefits in Q1.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q1 2026 Q1 2026 2026-05-14
Q1 2026 saw 15.9% revenue growth and 25.2% adjusted EBITDA growth, driven by preferred payer strategies and operational efficiencies. Guidance for 2026 was raised, and the Family First Homecare acquisition is set to close in late Q2.
Q4 2025 Q4 2025 2026-03-19
Q4 and full-year 2025 saw strong double-digit revenue and EBITDA growth, driven by improved rates, higher volumes, and cost efficiencies across all segments. 2026 guidance projects continued organic growth, further expansion of preferred payer agreements, and integration of the Family First acquisition, with leverage expected to remain stable.
Q3 2025 Q3 2025 2025-11-06
Q3 2025 saw 22.2% revenue growth and 67.5% adjusted EBITDA growth, driven by preferred payer strategies, rate enhancements, and the ThriveSkill Pediatrics acquisition. 2025 guidance was raised, with continued focus on margin expansion, cash flow, and disciplined capital allocation.
Q2 2025 Q2 2025 2025-08-07
Q2 2025 saw revenue rise 16.8% to $589.6M and adjusted EBITDA nearly double, driven by rate enhancements, preferred payer strategies, and operational efficiencies. 2025 guidance was raised, with revenue expected above $2.3B and adjusted EBITDA over $270M, including the Thrive acquisition.
Q1 2025 Q1 2025 2025-05-08
Q1 2025 saw 14% revenue growth and a 93% rise in adjusted EBITDA, driven by rate improvements and cost initiatives. Preferred payer agreements and government rate enhancements fueled segment growth, while the Thrive acquisition is set to expand presence and synergies.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.